Significant innovations in healthcare often require new ways of thinking to recognize their true value. It is the responsibility of the pharmaceutical industry to help drive change that can match healthcare spending to the most valuable innovations. In this poster, we assesses the challenges facing industry in preparing for innovation by synchronizing long-term investment in the broad policy environment with shorter-term market access strategy ahead of brand launch.
Rare disease PMA trends in France: Price achieved vs. disease prevalence
In this installment, we examine the relationship between launch prices in France and disease prevalence as reported in the Haute Autorité de Santé assessments.